ifinatamab deruxtecan
daiichi sankyo
['ds-7300', 'sclc']
adcs for sclc: highly needed!
ds-7300, an adc against b7-h3, induced a confirmed response in 10/19 (53%) patients. dor : 5.5 months. update of the subgroup analysis from the phase i/ii study that enrolled 147 patients. #esmo22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.